Literature DB >> 29756562

Perspectives and New Aspects of Metalloproteinases' Inhibitors in the Therapy of CNS Disorders: From Chemistry to Medicine.

Anna Boguszewska-Czubara1, Barbara Budzynska2, Krystyna Skalicka-Wozniak3, Jacek Kurzepa1.   

Abstract

Matrix metalloproteinases (MMPs) play a key role in remodeling of the extracellular matrix (ECM) and, at the same time, influence cell differentiation, migration, proliferation, and survival. Their importance in a variety of human diseases including cancer, rheumatoid arthritis, pulmonary emphysema and fibrotic disorders has been known for many years but special attention should be paid on the role of MMPs in the central nervous system (CNS) disorders. Till now, there are not many well documented physiological MMP target proteins in the brain but only some pathological ones. Numerous neurodegenerative diseases are a consequence of or result in disturbed remodeling of brain ECM, therefore proper action of MMPs as well as control of their activity may play crucial roles in the development of these diseases. In the present review, we discuss the role of metalloproteinase inhibitors, from the wellknown natural endogenous tissue inhibitors of metalloproteinases (TIMPs) to the exogenous synthetic ones like (4-phenoxyphenylsulfonyl)methylthiirane (SB-3CT), tetracyclines, batimastat (BB-94) and FN-439. As the MMP-TIMP system has been well described in physiological development as well as in pathological conditions mainly in neoplastic diseases, the knowledge about the enzymatic system in mammalian brain tissue still remains poorly understood in this context. Therefore, we focus on MMPs inhibition in the context of the physiological function of the adult brain as well as pathological conditions including neurodegenerative diseases, brain injuries, and others. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  CNS disorders; MMPs inhibition; TIMPs; brain; metalloproteinases; neoplasctic diseases.

Mesh:

Substances:

Year:  2019        PMID: 29756562     DOI: 10.2174/0929867325666180514111500

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  6 in total

Review 1.  Long Non-coding RNA in CNS Injuries: A New Target for Therapeutic Intervention.

Authors:  Li Zhang; Handong Wang
Journal:  Mol Ther Nucleic Acids       Date:  2019-07-29       Impact factor: 8.886

2.  Resin-dentin bond stability of etch-and-rinse adhesive systems with different concentrations of MMP inhibitor GM1489.

Authors:  Maria Elisa da Silva Nunes Gomes Miranda; Eduardo Moreira da Silva; Mariana Flôres de Oliveira; Fabiana Souza Simmer; Glauco Botelho Dos Santos; Cristiane Mariote Amaral
Journal:  J Appl Oral Sci       Date:  2020-04-27       Impact factor: 2.698

3.  Bee Venom Effect on Glioblastoma Cells Viability and Gelatinase Secretion.

Authors:  Agata Małek; Joanna Kocot; Kamila Mitrowska; Andrzej Posyniak; Jacek Kurzepa
Journal:  Front Neurosci       Date:  2022-02-11       Impact factor: 4.677

Review 4.  Incorporation of MMP inhibitors into dental adhesive systems and bond strength of coronal composite restorations: A systematic review and meta-analysis of in vitro studies.

Authors:  Rayan B Yaghmoor; Hasan Jamal; Hassan Abed; Elaine Allan; Paul Ashley; Anne Young
Journal:  Jpn Dent Sci Rev       Date:  2022-10-10

Review 5.  Long non-coding RNAs mediate cerebral vascular pathologies after CNS injuries.

Authors:  Mengqi Zhang; Milton H Hamblin; Ke-Jie Yin
Journal:  Neurochem Int       Date:  2021-06-18       Impact factor: 4.297

Review 6.  Matrix Metalloproteinases and Glaucoma Treatment.

Authors:  Robert N Weinreb; Michael R Robinson; Mohammed Dibas; W Daniel Stamer
Journal:  J Ocul Pharmacol Ther       Date:  2020-04-01       Impact factor: 2.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.